Taiko Pharmaceutical Sets 2026 Deadline to Restore TSE Prime Listing Compliance

An update from Taiko Pharmaceutical Co., Ltd. ( (JP:4574) ) is now available.

Taiko Pharmaceutical has fallen short of the Tokyo Stock Exchange Prime Market’s tradable share market capitalization requirement, with its freely traded share value at ¥9.0 billion at end-2025 versus the ¥10.0 billion threshold. The company has entered an improvement period through December 2026, during which failure to regain compliance could trigger supervision status or eventual delisting, or prompt a move to the Standard Market.

Management plans to lift market valuation and market cap by executing its Medium-Term Management Plan focused on sustainable growth and capital cost-aware management. Key measures include expanding pharmaceutical supply capacity, strengthening Seirogan’s position to target leadership in Asia’s gastrointestinal market, investing in new products under brands such as Rappa, restoring profitability in the Infection Control Business through B2B focus and cost controls, and advancing organizational and human capital reforms to enhance corporate value.

The most recent analyst rating on (JP:4574) stock is a Buy with a Yen351.00 price target. To see the full list of analyst forecasts on Taiko Pharmaceutical Co., Ltd. stock, see the JP:4574 Stock Forecast page.

More about Taiko Pharmaceutical Co., Ltd.

Taiko Pharmaceutical Co., Ltd. is a Japan-based drugmaker listed on the Tokyo Stock Exchange Prime Market, best known for over-the-counter gastrointestinal remedies such as the Seirogan brand. The company also operates an Infection Control Business, including Cleverin-branded products, with a growing focus on Asian markets, particularly Greater China, for gastrointestinal medicines.

Average Trading Volume: 163,642

Technical Sentiment Signal: Strong Sell

Current Market Cap: Yen14.37B

See more data about 4574 stock on TipRanks’ Stock Analysis page.